Skip to main content
Journal cover image

COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey.

Publication ,  Journal Article
Li, Y; Muppidi, S; Unnithan, S; Al-Khalidi, HR; Masterson, S; Huff, W; Juel, VC; Guptill, JT; Raja, SM
Published in: Muscle Nerve
October 2025

INTRODUCTION/AIMS: Patients with myasthenia gravis (MG) often receive immunosuppressive treatments. While approved COVID-19 vaccines effectively prevent severe infections, the impact of vaccination among immunocompromised MG patients remains unclear. This study explored vaccination status, adverse events, and post-vaccination outcomes among MG patients. METHODS: A REDCap survey was conducted between September 21, 2021 and November 18, 2021 through the Myasthenia Gravis Foundation of America to collect data on demographic and disease characteristics, COVID-19 infections, vaccination status, and precaution strategies. A follow-up survey was available from January 11, 2022 to March 8, 2022. RESULTS: A total of 1205 participants [65.7% female, average age 59.6 ± 15.4 years] completed the survey. Most were White or Caucasian (87.9%), 63.6% held a bachelor's degree or higher, and 41.9% were retired. Acetylcholine receptor (AChR) antibody positivity was reported by 47%, MuSK-Ab positivity by 6.1%, and 19.6% were seronegative. Most (75%) were on immunosuppressive therapy, and the vaccination rate was 91.5%. Among COVID-19 vaccine recipients, 61.5% reported adverse effects, while 8.5% of participants remained unvaccinated due to concerns about side effects (65%) and potential worsening of MG symptoms (70.9%). Post-vaccination COVID-19 infection rates dropped from 9.7% to 2.4%. Hospitalization decreased from 2.3% to 0.3%, and MG exacerbation rates from 5.5% to 1.4%. DISCUSSION: COVID-19 vaccination acceptance is high among MG patients. Reported side effects in MG patients were comparable to those in the general population, and vaccination was associated with a reduced COVID-19 infection rate. Addressing concerns about vaccine side effects and providing efficacy data specific to MG could aid unvaccinated individuals in decision-making.

Duke Scholars

Published In

Muscle Nerve

DOI

EISSN

1097-4598

Publication Date

October 2025

Volume

72

Issue

4

Start / End Page

597 / 605

Location

United States

Related Subject Headings

  • Vaccination
  • Surveys and Questionnaires
  • SARS-CoV-2
  • Receptors, Cholinergic
  • Neurology & Neurosurgery
  • Myasthenia Gravis
  • Middle Aged
  • Male
  • Longitudinal Studies
  • Immunosuppressive Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Li, Y., Muppidi, S., Unnithan, S., Al-Khalidi, H. R., Masterson, S., Huff, W., … Raja, S. M. (2025). COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey. Muscle Nerve, 72(4), 597–605. https://doi.org/10.1002/mus.28466
Li, Yingkai, Srikanth Muppidi, Shakthi Unnithan, Hussein R. Al-Khalidi, Samantha Masterson, Wendi Huff, Vern C. Juel, Jeffrey T. Guptill, and Shruti M. Raja. “COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey.Muscle Nerve 72, no. 4 (October 2025): 597–605. https://doi.org/10.1002/mus.28466.
Li Y, Muppidi S, Unnithan S, Al-Khalidi HR, Masterson S, Huff W, et al. COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey. Muscle Nerve. 2025 Oct;72(4):597–605.
Li, Yingkai, et al. “COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey.Muscle Nerve, vol. 72, no. 4, Oct. 2025, pp. 597–605. Pubmed, doi:10.1002/mus.28466.
Li Y, Muppidi S, Unnithan S, Al-Khalidi HR, Masterson S, Huff W, Juel VC, Guptill JT, Raja SM. COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey. Muscle Nerve. 2025 Oct;72(4):597–605.
Journal cover image

Published In

Muscle Nerve

DOI

EISSN

1097-4598

Publication Date

October 2025

Volume

72

Issue

4

Start / End Page

597 / 605

Location

United States

Related Subject Headings

  • Vaccination
  • Surveys and Questionnaires
  • SARS-CoV-2
  • Receptors, Cholinergic
  • Neurology & Neurosurgery
  • Myasthenia Gravis
  • Middle Aged
  • Male
  • Longitudinal Studies
  • Immunosuppressive Agents